Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Announces CRESTOR United States Patent Upheld by Court of Appeals for Federal Circuit


Saturday, 15 Dec 2012 02:00am EST 

AstraZeneca PLC announced that the Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the United States (US) substance patent protecting CRESTOR (rosuvastatin calcium) (RE37,314 – the ‘314 patent) is valid and enforceable. The defendants may seek a rehearing and/or review by the US Supreme Court. Absent a reversal of this decision, none of the Abbreviated New Drug Applications (ANDAs) filed by Apotex, Aurobindo, Cobalt, Glenmark, Mylan, Par, Sandoz, Sun, Teva and Torrent may be approved by the FDA prior to expiration of the ‘314 patent. The ‘314 patent, which expires in 2016, covers rosuvastatin calcium, the active ingredient in CRESTOR. The Federal Circuit also held that Apotex Corp. was liable as a submitter and is therefore bound by the District Court’s decision. 

Company Quote

4322.5
-38.5 -0.88%
29 Jul 2014